Recombinant Human FCRL1 protein

中文名： Fc受体样蛋白1(FCRL1)重组蛋白
别名： FCRL1；FCRH1；IFGP1；IRTA5；Fc receptor-like protein 1

货号: PA1000-6647

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>95%SDS-PAGE.
种属	Human
靶点	FCRL1
Uniprot No	Q96LA6
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	17-303aa
氨基酸序列	AELFLIASPSHPTEGSPVTLTCKMPFLQSSDAQFQFCFFRDTRALGPGWS SSPKLQIAAMWKEDTGSYWCEAQTMASKVLRSRRSQINVHRVPVADVSLE TQPPGGQVMEGDRLVLICSVAMGTGDITFLWYKGAVGLNLQSKTQRSLTA EYEIPSVRESDAEQYYCVAENGYGPSPSGLVSITVRIPVSRPILMLRAPR AQAAVEDVLELHCEALRGSPPILYWFYHEDITLGSRSAPSGGGASFNLSL TEEHSGNYSCEANNGLGAQRSEAVTLNFTVPTGARSNVDHHHHHH
预测分子量	32 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于FCRL1重组蛋白的3篇参考文献(注：以下为模拟内容，实际文献需通过学术数据库查询确认)：

---

1. **文献名称**：*"Recombinant FCRL1 Protein Suppresses B-Cell Activation via Interaction with the BCR Complex"*

**作者**：Wilson TJ, et al.

**摘要**：研究通过表达纯化FCRL1重组蛋白，发现其直接结合B细胞受体(BCR)，抑制抗原诱导的B细胞活化和下游信号通路，提示其负向调控免疫反应的机制。

---

2. **文献名称**：*"Structural and Functional Analysis of FCRL1 as a Co-Inhibitory Receptor in T Cells"*

**作者**：Davis RS, et al.

**摘要**：利用重组FCRL1胞外域蛋白进行结构解析和功能实验，揭示其与MHC II类分子的非经典结合模式，并证实其在T细胞中抑制共刺激信号，影响免疫耐受。

---

3. **文献名称**：*"FCRL1 Recombinant Protein Attenuates Autoantibody Production in Murine Lupus Models"*

**作者**：Li Y, et al.

**摘要**：在系统性红斑狼疮小鼠模型中，注射重组FCRL1蛋白显著减少自身抗体产生和肾脏损伤，表明其通过调节浆细胞分化发挥治疗潜力。

---

建议通过PubMed或Google Scholar以“FCRL1 recombinant protein”为关键词检索最新文献以获取准确信息。

背景信息

Fc receptor-like 1 (FCRL1) is a transmembrane glycoprotein belonging to the Fc receptor-like (FCRL) family, which shares structural homology with classical Fc receptors but lacks direct Fc-binding capacity. Primarily expressed in B lymphocytes, FCRL1 is implicated in modulating immune responses through its immunoregulatory functions. It contains extracellular immunoglobulin-like domains and cytoplasmic tyrosine-based signaling motifs, suggesting roles in both ligand interaction and intracellular signaling.

FCRL1 has garnered attention for its dual roles in immune regulation. Studies suggest it may act as a co-inhibitory receptor, dampening B-cell receptor (BCR) signaling to prevent hyperactivation, while other evidence points to its potential in promoting B-cell survival under specific conditions. Its expression pattern is altered in autoimmune diseases (e.g., rheumatoid arthritis, lupus) and B-cell malignancies, positioning it as a potential biomarker or therapeutic target.

Recombinant FCRL1 protein, typically produced in mammalian expression systems, retains the extracellular domain to study ligand interactions and signaling mechanisms. This engineered protein enables researchers to investigate FCRL1's binding partners, such as putative ligands on T cells or antigens, and its influence on immune synapse formation. Additionally, it serves as a tool for developing antibodies or inhibitors targeting FCRL1 in immunotherapy.

Current research focuses on resolving contradictory findings about FCRL1's activating versus inhibitory effects, clarifying its physiological ligands, and exploring its therapeutic potential in autoimmune disorders and cancers. The recombinant protein's availability accelerates mechanistic studies and drug discovery efforts in B-cell-mediated pathologies.